Within the first quarter, Pictet Asset Management Ltd. lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 4.6%, in accordance to its most recent Form 13F filing with the Securities and Exchange Comission. The firm had ownership of 1,362,755 shares of the stock of the biotech company which was after buying an additional 59,728 shares during the quarter. Pictet Asset Management Ltd. had ownership of about 0.76% of BioMarin Pharmaceutical which was worth $121,054,000 at the end of the most recent period of reporting.
Other institutional investors and hedge funds, too have made variations to their positions in the company. Doyle Wealth Management bought a new position in the shares of BioMarin Pharmaceutical in the 4th quarter which was worth approximately $26,000. Rational Advisors LLC brought up its position in shares of BioMarin Pharmaceutical by by 3,211.1% in the 1st quarter. Rational Advisors LLC now has ownership of 298 shares of the stock of this biotech company which is worth $26,000 which is after the acquiring of 298 shares in the last quarter. Commonwealth Bank of Australia brought up its position in Biomarin Pharmaceutical by 49.6% in the 4th quarter and now they own 350 shares of the biotech company’s stock which is worth $29,000 that is, after the obtaining of 116 shares in the last quarter. Lindbrook capital LLC bought a new position in the BioMarin Pharmaceutical shares in the 4th quarter which was worth about $30,000. Finally, PRE Wealth management LLC bought a new position in the shares of BioMarin Pharmaceutical in the 4th quarter which was worth about $30,000. A large, 98.48% of the stock is in ownership of hedge funds and certain other institutional investors.
In other related news, the CEO Jean Jacques Bienaime sold out 4,000 shares of the stocks in the business in a transaction on Thursday, March 7th. The stock was sold at a mean price of $90.78, amounting to a total transaction of $363, 120,00. After the transaction, the chief executive officer now directly has ownership of 332,701 shares of the stock of the company which is worth $30, 202, 596, 78. Moreover, Director V Bryan Lawlis has sold 2,150 shares of the stocks of the business in a transaction that happened on Wednesday, March 27th. The stock was sold at an a mean price of $89.76 which amounts to a sum total of $192, 984,00. After the transaction, the directior now has direct ownership of 21,310 shares in the company which is worth $1, 912, 785, 60. Insiders have sold a sum total of 93,815 shares of the company stock which is worth $8,369,268 in the final quarter. Company insiders now have ownership of 1.97% of the company’s stock.